212 related articles for article (PubMed ID: 30595191)
21. Immunotherapy in advanced gastric cancer, is it the future?
Coutzac C; Pernot S; Chaput N; Zaanan A
Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
[TBL] [Abstract][Full Text] [Related]
22. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
23. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.
Ribas A; Tumeh PC
Clin Cancer Res; 2014 Oct; 20(19):4982-4. PubMed ID: 24970841
[TBL] [Abstract][Full Text] [Related]
24. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
25. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
26. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
29. [Precision medicine and immuno-radiotherapy].
Chargari C; Robert C; Genestie C; Deutsch E
Cancer Radiother; 2021 Oct; 25(6-7):570-575. PubMed ID: 34391650
[TBL] [Abstract][Full Text] [Related]
30. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Nowicki TS; Hu-Lieskovan S; Ribas A
Cancer J; 2018; 24(1):47-53. PubMed ID: 29360728
[TBL] [Abstract][Full Text] [Related]
32. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Passardi A; Canale M; Valgiusti M; Ulivi P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635639
[TBL] [Abstract][Full Text] [Related]
34. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Baldini C; Romano PM; Varga A; Champiat S; Dumont S; Dhermain F; Louvel G; Marabelle A; Postel-Vinay S; Angevin E; Gazzah A; Ribrag V; Bahleda R; Michot JM; Hollebecque A; Soria JC; Massard C
Bull Cancer; 2018 Dec; 105 Suppl 1():S59-S67. PubMed ID: 30595200
[TBL] [Abstract][Full Text] [Related]
38. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
